Autolus Therapeutics plc, a biopharmaceutical company listed on Nasdaq, announced on July 15, 2025, that its Board of Directors' compensation committee has granted stock option awards to 60 employees under the 2025 Inducement Plan. These options allow for the purchase of a total of 360,550 shares of common stock at an exercise price of $2.47 per share, matching the closing price on July 9, 2025. Each option comes with a ten-year term and vests over four years, with 25% vesting after the first year and the remainder vesting in equal monthly installments over the following three years, contingent on ongoing employment with Autolus.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.